vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and International Paper (IP). Click either name above to swap in a different company.

Bristol Myers Squibb is the larger business by last-quarter revenue ($11.5B vs $6.0B, roughly 1.9× International Paper). Bristol Myers Squibb runs the higher net margin — 23.3% vs 1.0%, a 22.3% gap on every dollar of revenue. On growth, Bristol Myers Squibb posted the faster year-over-year revenue change (11.0% vs -0.6%). Over the past eight quarters, International Paper's revenue compounded faster (12.3% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

The International Paper Company is an American pulp and paper company, the largest such company in the world. It has approximately 39,000 employees, and is headquartered in Memphis, Tennessee.

BMY vs IP — Head-to-Head

Bigger by revenue
BMY
BMY
1.9× larger
BMY
$11.5B
$6.0B
IP
Growing faster (revenue YoY)
BMY
BMY
+11.6% gap
BMY
11.0%
-0.6%
IP
Higher net margin
BMY
BMY
22.3% more per $
BMY
23.3%
1.0%
IP
Faster 2-yr revenue CAGR
IP
IP
Annualised
IP
12.3%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BMY
BMY
IP
IP
Revenue
$11.5B
$6.0B
Net Profit
$2.7B
$60.0M
Gross Margin
Operating Margin
Net Margin
23.3%
1.0%
Revenue YoY
11.0%
-0.6%
Net Profit YoY
8.8%
157.1%
EPS (diluted)
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
IP
IP
Q1 26
$11.5B
$6.0B
Q4 25
$12.5B
$4.7B
Q3 25
$12.2B
$6.2B
Q2 25
$12.3B
$6.8B
Q1 25
$11.2B
$5.9B
Q4 24
$12.3B
$4.6B
Q3 24
$11.9B
$4.7B
Q2 24
$12.2B
$4.7B
Net Profit
BMY
BMY
IP
IP
Q1 26
$2.7B
$60.0M
Q4 25
$1.1B
$-2.4B
Q3 25
$2.2B
$-1.1B
Q2 25
$1.3B
$75.0M
Q1 25
$2.5B
$-105.0M
Q4 24
$72.0M
$-147.0M
Q3 24
$1.2B
$150.0M
Q2 24
$1.7B
$498.0M
Gross Margin
BMY
BMY
IP
IP
Q1 26
Q4 25
67.2%
32.2%
Q3 25
71.9%
31.1%
Q2 25
72.5%
27.9%
Q1 25
72.9%
27.8%
Q4 24
61.0%
29.0%
Q3 24
75.1%
28.7%
Q2 24
73.2%
29.0%
Operating Margin
BMY
BMY
IP
IP
Q1 26
Q4 25
11.8%
-56.4%
Q3 25
25.5%
-10.8%
Q2 25
14.5%
1.7%
Q1 25
26.5%
-2.3%
Q4 24
1.4%
-4.9%
Q3 24
14.1%
5.1%
Q2 24
10.5%
6.8%
Net Margin
BMY
BMY
IP
IP
Q1 26
23.3%
1.0%
Q4 25
8.7%
-50.3%
Q3 25
18.0%
-17.7%
Q2 25
10.7%
1.1%
Q1 25
21.9%
-1.8%
Q4 24
0.6%
-3.2%
Q3 24
10.2%
3.2%
Q2 24
13.8%
10.5%
EPS (diluted)
BMY
BMY
IP
IP
Q1 26
$0.14
Q4 25
$0.54
$-4.76
Q3 25
$1.08
$-2.09
Q2 25
$0.64
$0.14
Q1 25
$1.20
$-0.24
Q4 24
$0.05
$-0.42
Q3 24
$0.60
$0.42
Q2 24
$0.83
$1.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
IP
IP
Cash + ST InvestmentsLiquidity on hand
$9.6B
Total DebtLower is stronger
$-42.2B
$8.2B
Stockholders' EquityBook value
$14.8B
Total Assets
$36.4B
Debt / EquityLower = less leverage
0.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
IP
IP
Q1 26
$9.6B
Q4 25
$10.2B
$1.1B
Q3 25
$15.7B
$995.0M
Q2 25
$12.6B
$1.1B
Q1 25
$10.9B
$1.2B
Q4 24
$10.3B
$1.2B
Q3 24
$7.9B
$1.2B
Q2 24
$6.3B
$1.0B
Total Debt
BMY
BMY
IP
IP
Q1 26
$-42.2B
$8.2B
Q4 25
$44.8B
$8.8B
Q3 25
$48.7B
$9.0B
Q2 25
$48.9B
$9.7B
Q1 25
$49.5B
$9.2B
Q4 24
$49.4B
$5.4B
Q3 24
$49.5B
$5.3B
Q2 24
$52.0B
$5.3B
Stockholders' Equity
BMY
BMY
IP
IP
Q1 26
$14.8B
Q4 25
$18.5B
$14.8B
Q3 25
$18.6B
$17.3B
Q2 25
$17.4B
$18.6B
Q1 25
$17.4B
$18.1B
Q4 24
$16.3B
$8.2B
Q3 24
$17.1B
$8.6B
Q2 24
$17.0B
$8.6B
Total Assets
BMY
BMY
IP
IP
Q1 26
$36.4B
Q4 25
$90.0B
$38.0B
Q3 25
$96.9B
$40.6B
Q2 25
$94.7B
$42.4B
Q1 25
$92.4B
$41.2B
Q4 24
$92.6B
$22.8B
Q3 24
$93.7B
$23.2B
Q2 24
$94.6B
$23.1B
Debt / Equity
BMY
BMY
IP
IP
Q1 26
0.55×
Q4 25
2.43×
0.60×
Q3 25
2.63×
0.52×
Q2 25
2.81×
0.52×
Q1 25
2.85×
0.51×
Q4 24
3.03×
0.66×
Q3 24
2.89×
0.62×
Q2 24
3.05×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
IP
IP
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$94.0M
FCF MarginFCF / Revenue
1.6%
Capex IntensityCapex / Revenue
8.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$553.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
IP
IP
Q1 26
Q4 25
$2.0B
$905.0M
Q3 25
$6.3B
$605.0M
Q2 25
$3.9B
$476.0M
Q1 25
$2.0B
$-288.0M
Q4 24
$4.4B
$397.0M
Q3 24
$5.6B
$521.0M
Q2 24
$2.3B
$365.0M
Free Cash Flow
BMY
BMY
IP
IP
Q1 26
$94.0M
Q4 25
$1.6B
$255.0M
Q3 25
$6.0B
$150.0M
Q2 25
$3.6B
$54.0M
Q1 25
$1.7B
$-618.0M
Q4 24
$4.1B
$137.0M
Q3 24
$5.3B
$309.0M
Q2 24
$2.1B
$167.0M
FCF Margin
BMY
BMY
IP
IP
Q1 26
1.6%
Q4 25
12.8%
5.4%
Q3 25
49.0%
2.4%
Q2 25
29.0%
0.8%
Q1 25
15.1%
-10.5%
Q4 24
32.9%
3.0%
Q3 24
44.3%
6.6%
Q2 24
16.9%
3.5%
Capex Intensity
BMY
BMY
IP
IP
Q1 26
8.7%
Q4 25
3.0%
13.7%
Q3 25
2.6%
7.3%
Q2 25
2.9%
6.2%
Q1 25
2.3%
5.6%
Q4 24
3.1%
5.7%
Q3 24
2.7%
4.5%
Q2 24
2.1%
4.2%
Cash Conversion
BMY
BMY
IP
IP
Q1 26
Q4 25
1.82×
Q3 25
2.87×
Q2 25
2.99×
6.35×
Q1 25
0.80×
Q4 24
61.65×
Q3 24
4.62×
3.47×
Q2 24
1.38×
0.73×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMY
BMY

Segment breakdown not available.

IP
IP

Packaging Solutions North America$3.6B61%
Packaging Solutions EMEA$2.3B39%
Corporate and Inter-segment Sales$22.0M0%

Related Comparisons